304 related articles for article (PubMed ID: 32852568)
1. The beneficial effects of reducing NLRP3 inflammasome activation in the cardiotoxicity and the anti-cancer effects of doxorubicin.
Maayah ZH; Takahara S; Dyck JRB
Arch Toxicol; 2021 Jan; 95(1):1-9. PubMed ID: 32852568
[TBL] [Abstract][Full Text] [Related]
2. Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1.
Sun Z; Lu W; Lin N; Lin H; Zhang J; Ni T; Meng L; Zhang C; Guo H
Biochem Pharmacol; 2020 May; 175():113888. PubMed ID: 32112883
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D1 receptor alleviates doxorubicin-induced cardiac injury by inhibiting NLRP3 inflammasome.
Liu J; Jin Y; Wang B; Wang Y; Zuo S; Zhang J
Biochem Biophys Res Commun; 2021 Jul; 561():7-13. PubMed ID: 33992835
[TBL] [Abstract][Full Text] [Related]
4. Involvement of ROS/NLRP3 Inflammasome Signaling Pathway in Doxorubicin-Induced Cardiotoxicity.
Wei S; Ma W; Li X; Jiang C; Sun T; Li Y; Zhang B; Li W
Cardiovasc Toxicol; 2020 Oct; 20(5):507-519. PubMed ID: 32607760
[TBL] [Abstract][Full Text] [Related]
5. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis.
Zhang L; Jiang YH; Fan C; Zhang Q; Jiang YH; Li Y; Xue YT
Biomed Pharmacother; 2021 Nov; 143():112133. PubMed ID: 34474337
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin induces cardiomyocyte pyroptosis via the TINCR-mediated posttranscriptional stabilization of NLR family pyrin domain containing 3.
Meng L; Lin H; Zhang J; Lin N; Sun Z; Gao F; Luo H; Ni T; Luo W; Chi J; Guo H
J Mol Cell Cardiol; 2019 Nov; 136():15-26. PubMed ID: 31445005
[TBL] [Abstract][Full Text] [Related]
7. Targeting heat shock protein 47 alleviated doxorubicin-induced cardiotoxicity and remodeling in mice through suppression of the NLRP3 inflammasome.
Shi W; Chen J; Zhao N; Xing Y; Liu S; Chen M; Fang W; Zhang T; Li L; Zhang H; Zhang M; Zeng X; Chen S; Wang S; Xie S; Deng W
J Mol Cell Cardiol; 2024 Jan; 186():81-93. PubMed ID: 37995517
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol reduces cardiac NLRP3-inflammasome activation and systemic inflammation to lessen doxorubicin-induced cardiotoxicity in juvenile mice.
Maayah ZH; Alam AS; Takahara S; Soni S; Ferdaoussi M; Matsumura N; Zordoky BN; Eisenstat DD; Dyck JRB
FEBS Lett; 2021 Jun; 595(12):1681-1695. PubMed ID: 33876420
[TBL] [Abstract][Full Text] [Related]
9. The NLRP3 Inflammasome as a Pharmacological Target.
Marchetti C
J Cardiovasc Pharmacol; 2019 Oct; 74(4):285-296. PubMed ID: 31335445
[TBL] [Abstract][Full Text] [Related]
10. Targeting NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome in Cardiovascular Disorders.
Wang Z; Hu W; Lu C; Ma Z; Jiang S; Gu C; Acuña-Castroviejo D; Yang Y
Arterioscler Thromb Vasc Biol; 2018 Dec; 38(12):2765-2779. PubMed ID: 30571177
[TBL] [Abstract][Full Text] [Related]
11. Cell-Specific Roles of NLRP3 Inflammasome in Myocardial Infarction.
Takahashi M
J Cardiovasc Pharmacol; 2019 Sep; 74(3):188-193. PubMed ID: 31356542
[TBL] [Abstract][Full Text] [Related]
12. Honokiol antagonizes doxorubicin‑induced cardiomyocyte senescence by inhibiting TXNIP‑mediated NLRP3 inflammasome activation.
Huang PP; Fu J; Liu LH; Wu KF; Liu HX; Qi BM; Liu Y; Qi BL
Int J Mol Med; 2020 Jan; 45(1):186-194. PubMed ID: 31746354
[TBL] [Abstract][Full Text] [Related]
13. Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis.
Tavakoli Dargani Z; Singla DK
Am J Physiol Heart Circ Physiol; 2019 Aug; 317(2):H460-H471. PubMed ID: 31172809
[TBL] [Abstract][Full Text] [Related]
14. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
Quagliariello V; De Laurentiis M; Rea D; Barbieri A; Monti MG; Carbone A; Paccone A; Altucci L; Conte M; Canale ML; Botti G; Maurea N
Cardiovasc Diabetol; 2021 Jul; 20(1):150. PubMed ID: 34301253
[TBL] [Abstract][Full Text] [Related]
15. SIRT3 attenuates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome via autophagy.
Sun Z; Fang C; Xu S; Wang B; Li D; Liu X; Mi Y; Guo H; Jiang J
Biochem Pharmacol; 2023 Jan; 207():115354. PubMed ID: 36435202
[TBL] [Abstract][Full Text] [Related]
16. Nicotinamide mononucleotide attenuates doxorubicin-induced cardiotoxicity by reducing oxidative stress, inflammation and apoptosis in rats.
Wan Y; He B; Zhu D; Wang L; Huang R; Zhu J; Wang C; Gao F
Arch Biochem Biophys; 2021 Nov; 712():109050. PubMed ID: 34610336
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes.
Buckley LF; Libby P
J Cardiovasc Pharmacol; 2019 Oct; 74(4):297-305. PubMed ID: 31356538
[TBL] [Abstract][Full Text] [Related]
18. NLRP3 Inflammasome in Cardioprotective Signaling.
Zuurbier CJ
J Cardiovasc Pharmacol; 2019 Oct; 74(4):271-275. PubMed ID: 31356546
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of NR4A1 alleviates doxorubicin-induced cardiotoxicity through inhibiting the activation of the NLRP3 inflammasome.
Hu H; Zhong Z; Meng L; Chen J; Yu Z; Lu K
Biochem Biophys Res Commun; 2024 Mar; 700():149582. PubMed ID: 38306930
[TBL] [Abstract][Full Text] [Related]
20. Astragaloside IV Alleviates Doxorubicin-Induced Cardiotoxicity by Inhibiting Cardiomyocyte Pyroptosis through the SIRT1/NLRP3 Pathway.
Tian W; Zhang P; Yang L; Song P; Zhao J; Wang H; Zhao Y; Cao L
Am J Chin Med; 2024; 52(2):453-469. PubMed ID: 38490806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
